2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
Blood Specimen Collection
9
Surveys and Questionnaires
6
Magnetic Resonance Spectroscopy
6
Dexamethasone
6
Cyclophosphamide
6
Prednisone
5
Mammography
5
Colonoscopy
5
Biopsy
5
Positron Emission Tomography Computed Tomography
4
Magnetic Resonance Imaging
4
Lenalidomide
4
Biopsy, Fine-Needle
4
pembrolizumab
3
Tomography, X-Ray Computed
3
Surgical Procedures, Operative
3
Melphalan
3
Liquid Biopsy
3
Interviews as Topic
3
Exercise
3
Diagnostic Tests, Routine
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
weifuchun
2
obinutuzumab
2
fluciclovine F-18
2
daratumumab
2
carfilzomib
2
Urination
2
Preoperative Exercise
2
Positron-Emission Tomography
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease
×
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled